Mirna Therapeutics Financials

$78.7 M

Mkt cap, 16-Feb-2018
Cash, 31-Dec-201616.4 M

Market Value

Revenue/Financials

Income Statement

Annual

USDFY, 2015FY, 2016

R&D expense

18.9 m13.9 m

General and administrative expense

6.1 m8.1 m

Operating expense total

25 m22 m

Interest income

44 k350 k

Net Income

(25 m)(26.3 m)

Quarterly

USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

R&D expense

4.5 m3.7 m3.4 m242 k5.1 m

General and administrative expense

1.6 m2.1 m2 m1.9 m2.3 m4.2 m

Operating expense total

6.2 m6.7 m5.7 m5.3 m2.5 m9.5 m

Interest expense

8 k

Interest income

82 k93 k97 k86 k95 k

Net Income

(6.2 m)(6.6 m)(5.6 m)(5.4 m)

Balance Sheet

Annual

USDFY, 2015FY, 2016

Cash

89.7 m16.4 m

Inventories

793 k882 k

Current Assets

90.5 m61.4 m

PP&E

375 k354 k

Total Assets

90.9 m64.2 m

Accounts Payable

3.7 m361 k

Current Liabilities

5.9 m2.8 m

Total Liabilities

3.8 m

Additional Paid-in Capital

161.5 m163.1 m

Retained Earnings

(76.5 m)(102.8 m)

Total Equity

85 m60.4 m

Financial Leverage

1.1 x1.1 x

Quarterly

USDQ3, 2015

Cash

35.7 m

Current Assets

36.1 m

PP&E

266 k

Total Assets

38.1 m

Accounts Payable

2.2 m

Current Liabilities

5 m

Retained Earnings

(67.7 m)

Cash Flow

Annual

USDFY, 2015FY, 2016

Net Income

(25 m)(26.3 m)

Depreciation and Amortization

54 k159 k

Inventories

793 k107 k

Accounts Payable

3.7 m(3.3 m)

Cash From Operating Activities

(21.1 m)(24.8 m)

Purchases of PP&E

(251 k)(1.7 m)

Cash From Investing Activities

(251 k)(48.5 m)

Cash From Financing Activities

67 k16 k

Quarterly

USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(6.2 m)(6.6 m)(5.6 m)(5.4 m)

Accounts Payable

2.2 m1.2 m1.5 m1.2 m371 k47 k

Operating Metrics

FY, 2016

Patents Issued

10

Patents Pending

42